Phase III Trial Initiated for BLP25 Liposome Vaccine in Breast Cancer Patients

Publication
Article
OncologyONCOLOGY Vol 23 No 8
Volume 23
Issue 8

Merck KGaA of Darmstadt, Germany, has initiated a global phase III trial of BLP25 liposome vaccine (L-BLP25, Stimuvax) in patients with hormone receptor–positive, locally advanced, recurrent or metastatic breast cancer.

Merck KGaA of Darmstadt, Germany, has initiated a global phase III trial of BLP25 liposome vaccine (L-BLP25, Stimuvax) in patients with hormone receptor–positive, locally advanced, recurrent or metastatic breast cancer. L-BLP25 is an investigational therapeutic cancer vaccine being developed by Merck KGaA under a license agreement with Oncothyreon.

The phase III placebo-controlled trial, named STRIDE (STimulating immune Response In aDvanced brEast cancer), is anticipated to enroll more than 900 patients at approximately 180 sites in over 30 countries. The primary endpoint of STRIDE is progressionfree survival. Overall survival, quality of life, tumor response, and safety will also be assessed.

Articles in this issue
Resolving Confusion: The New Realities of Mantle Cell Lymphoma
Something Old, Something New: Options for Treating Relapsed Mantle Cell Lymphoma
Supraclavicular Extraskeletal Myxoid Chondrosarcoma Presenting With a Sensorimotor Polyneuropathy Associated With Anti-Hu Antibodies
Supraclavicular Extraskeletal Myxoid Chondrosarcoma Presenting With a Sensorimotor Polyneuropathy Associated With Anti-Hu Antibodies
Reishi Mushroom
Reishi Mushroom
Unraveling the Mystery of a Supraclavicular Mass
Management of Relapsed Mantle Cell Lymphoma: Still a Treatment Challenge
Sunitinib Improves Progression-Free Survival in Patients With Advanced Pancreatic Islet Cell Tumors
Phase III Trial Initiated for BLP25 Liposome Vaccine in Breast Cancer Patients
US Oncology Launches Oncology-Specific EHR
Effective Local Therapy and Long-Term Survival in Breast Cancer
Local Therapy Matters
Deemphasize Dogma: Consider the Local Control–Overall Survival Link
Romiplostim for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura
The Road to Romiplostim Approval and Beyond
The REMS Publication Paradox

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
Following progression on a CDK4/6 inhibitor, ascertaining the endocrine sensitivity of HR-positive/HER2-negative disease may inform sequential treatment.
T-DXd improved progression-free survival over standard chemotherapy among patients with HR-positive/triple-negative breast cancer in DESTINY-Breast04.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Multidisciplinary care can help ensure that treatment planning does not deviate from established guidelines for inflammatory breast cancer management.
Related Content
10 AI as a Bridge: Can ChatGPT Help Patients Understand Their Breast Radiology Reports?

10 AI as a Bridge: Can ChatGPT Help Patients Understand Their Breast Radiology Reports?

Siya Patil;Emily Rooney;Hemal Grover;Christine Chen
July 8th 2025
Article
Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS
April 21st 2025
Podcast

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Survival benefit was observed in heavily pretreated populations, including those who progressed after checkpoint inhibition and antibody drug conjugates.

Bria-IMT Yields Updated Survival Benefit in Metastatic Breast Cancer

Roman Fabbricatore
July 8th 2025
Article

Survival benefit was observed in heavily pretreated populations, including those who progressed after checkpoint inhibition and antibody drug conjugates.

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

SABCS 2024 Data Show ‘Great Steps Forward’ in Breast Cancer Care

Paolo Tarantino, MD;Matteo Lambertini, MD
January 13th 2025
Podcast

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

Phase 3 data affirm the use of partial-breast intensity-modulated radiotherapy as a standard of care in patients with low-risk early-stage breast cancer.

Partial-Breast Radiation Appears Effective, Safe in Early Breast Cancer

Russ Conroy
July 7th 2025
Article

Phase 3 data affirm the use of partial-breast intensity-modulated radiotherapy as a standard of care in patients with low-risk early-stage breast cancer.

As AI revolutionizes cancer care by enhancing diagnosis, treatment, and clinical trial matching, it may lead to improved patient outcomes and streamlined workflows.

Current Use and Future Directions of Artificial Intelligence in Hematology/Oncology

Julie M. Vose, MD, MBA
July 5th 2025
Article

As AI revolutionizes cancer care by enhancing diagnosis, treatment, and clinical trial matching, it may lead to improved patient outcomes and streamlined workflows.